Back to top
more

Galapagos (GLPG)

(Real Time Quote from BATS)

$28.65 USD

28.65
25,787

+0.02 (0.07%)

Updated Apr 26, 2024 12:31 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for GLPG

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Galapagos NV [GLPG]

Reports for Purchase

Showing records 1 - 20 ( 27 total )

Company: Galapagos NV

Industry: Medical - Biomedical and Genetics

Record: 1

11/21/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for GLPG 112123

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Galapagos NV

Industry: Medical - Biomedical and Genetics

Record: 2

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for GLPG

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Galapagos NV

Industry: Medical - Biomedical and Genetics

Record: 3

10/08/2020

Company Report

Pages: 3

Termination of Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Galapagos NV

Industry: Medical - Biomedical and Genetics

Record: 4

08/24/2020

Company Report

Pages: 17

Filgotinib CRL Puts High Risk Pipeline in Focus; Lowering to Neutral and Target Reduced to $123

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 50.00

Research Provided by a Third Party

Company: Galapagos NV

Industry: Medical - Biomedical and Genetics

Record: 5

08/10/2020

Company Report

Pages: 9

2Q20 Update; Looking Beyond Filgotinib to Other Pipeline Readouts During 2H20

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Galapagos NV

Industry: Medical - Biomedical and Genetics

Record: 6

07/24/2020

Company Report

Pages: 3

A Step Towards Potential Commercial Differentiation

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: Galapagos NV

Industry: Medical - Biomedical and Genetics

Record: 7

05/21/2020

Company Report

Pages: 11

A Stat-Sig Phase 3 Win; But Commercial Impact and MANTA Uncertainties Loom; Target Lowered to $270

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Galapagos NV

Industry: Medical - Biomedical and Genetics

Record: 8

05/11/2020

Company Report

Pages: 11

SELECTION Phase 3 Readout a Couple of Weeks out Plus Our Cheat Sheet on Historic UC Phase 3 Outcomes

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Galapagos NV

Industry: Medical - Biomedical and Genetics

Record: 9

03/23/2020

Industry Report

Pages: 4

Revisiting 2020 Catalyst Calendar

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: Galapagos NV

Industry: Medical - Biomedical and Genetics

Record: 10

03/02/2020

Industry Report

Pages: 7

From TINA to Cash Is King and Other Musings

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Galapagos NV

Industry: Medical - Biomedical and Genetics

Record: 11

02/24/2020

Company Report

Pages: 9

Staying the Course for Now and Raising Target to $302

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Galapagos NV

Industry: Medical - Biomedical and Genetics

Record: 12

02/21/2020

Industry Report

Pages: 7

Bringing a Wallet to a Hammer and Sickle Fight, and Other Tidbits

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Galapagos NV

Industry: Medical - Biomedical and Genetics

Record: 13

02/14/2020

Industry Report

Pages: 7

Runners up Is the New Killing It, and Other Tidbits

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Galapagos NV

Industry: Medical - Biomedical and Genetics

Record: 14

02/07/2020

Daily Note

Pages: 9

LetÂ’s Caucus, or Never Again; In an Otherwise Ho-Hum Earnings Week

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Galapagos NV

Industry: Medical - Biomedical and Genetics

Record: 15

01/09/2020

Daily Note

Pages: 18

2020 Catalyst Calendar and Top Picks Across Mid, Small, and Micro Caps

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 50.00

Research Provided by a Third Party

Company: Galapagos NV

Industry: Medical - Biomedical and Genetics

Record: 16

10/28/2019

Company Report

Pages: 10

Consolidation Post Gilead Transaction; Model Updates Post 3Q19

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Galapagos NV

Industry: Medical - Biomedical and Genetics

Record: 17

09/04/2019

Industry Report

Pages: 13

2H19 Value Drivers Within Our Coverage Universe

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 50.00

Research Provided by a Third Party

Company: Galapagos NV

Industry: Medical - Biomedical and Genetics

Record: 18

08/19/2019

Company Report

Pages: 11

Thoughts Post C-Suite Investor Meetings

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Galapagos NV

Industry: Medical - Biomedical and Genetics

Record: 19

07/29/2019

Company Report

Pages: 10

1H19 Corporate and Model Update

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Galapagos NV

Industry: Medical - Biomedical and Genetics

Record: 20

07/15/2019

Company Report

Pages: 8

Gilead Opts for Decentralized R-D Model With a $5.1B Collaboration; Target to $205 From $150

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party